A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae

NCT07647029 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)

Interventions

DRUG: Continuous Hetrombopag for 2 Cycles
DRUG: Cyclic 14-day Hetrombopag for 2 Cycles

Sponsor

Fudan University